Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biogen (BIIB) and Pacira Pharmaceuticals (PCRX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNYResearch Report), Biogen (BIIBResearch Report) and Pacira Pharmaceuticals (PCRXResearch Report).

Alnylam Pharma (ALNY)

In a report released yesterday, Zhiqiang Shu from Berenberg Bank maintained a Hold rating on Alnylam Pharma, with a price target of $154.00. The company’s shares closed last Thursday at $151.67.

According to TipRanks.com, Shu has 0 stars on 0-5 stars ranking scale with an average return of -11.8% and a 26.6% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics.

Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $215.35.

See the top stocks recommended by analysts >>

Biogen (BIIB)

In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Biogen, with a price target of $363.00. The company’s shares closed last Thursday at $239.66, close to its 52-week low of $221.72.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 11.8% and a 53.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Zentalis Pharmaceuticals, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $330.75, implying a 37.6% upside from current levels. In a report issued on December 22, Oppenheimer also maintained a Buy rating on the stock with a $350.00 price target.

Pacira Pharmaceuticals (PCRX)

Needham analyst Serge Belanger maintained a Buy rating on Pacira Pharmaceuticals today and set a price target of $84.00. The company’s shares closed last Thursday at $61.26.

According to TipRanks.com, Belanger is a 2-star analyst with an average return of 1.3% and a 38.3% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and KalVista Pharmaceuticals.

Pacira Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $81.50, implying a 36.0% upside from current levels. In a report issued on January 3, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $83.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALNY: